BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 352 filers reported holding BIO-TECHNE CORP in Q1 2019. The put-call ratio across all filers is 1.52 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $3,990,235 | -42.0% | 53,784 | -35.2% | 0.01% | -44.0% |
| Q4 2022 | $6,878,045 | +7.5% | 82,988 | +268.2% | 0.02% | -16.7% |
| Q3 2022 | $6,401,000 | -43.4% | 22,537 | -30.9% | 0.03% | -37.5% |
| Q2 2022 | $11,303,000 | +3.3% | 32,606 | +29.0% | 0.05% | +26.3% |
| Q1 2022 | $10,946,000 | -4.8% | 25,279 | +13.7% | 0.04% | +2.7% |
| Q4 2021 | $11,499,000 | +8.8% | 22,227 | +1.9% | 0.04% | 0.0% |
| Q3 2021 | $10,566,000 | +40.9% | 21,806 | +30.9% | 0.04% | +42.3% |
| Q2 2021 | $7,500,000 | -13.9% | 16,657 | -27.0% | 0.03% | -31.6% |
| Q1 2021 | $8,711,000 | -23.7% | 22,808 | -36.5% | 0.04% | -24.0% |
| Q4 2020 | $11,414,000 | +158.6% | 35,944 | +101.8% | 0.05% | +194.1% |
| Q3 2020 | $4,413,000 | -49.3% | 17,813 | -45.9% | 0.02% | -61.4% |
| Q2 2020 | $8,702,000 | +120.2% | 32,954 | +58.1% | 0.04% | +69.2% |
| Q1 2020 | $3,952,000 | -54.1% | 20,840 | -46.9% | 0.03% | -7.1% |
| Q4 2019 | $8,610,000 | +458.4% | 39,224 | +397.6% | 0.03% | +366.7% |
| Q3 2019 | $1,542,000 | -68.4% | 7,882 | -66.3% | 0.01% | -66.7% |
| Q2 2019 | $4,874,000 | -15.1% | 23,378 | -19.2% | 0.02% | -18.2% |
| Q1 2019 | $5,741,000 | +73.3% | 28,916 | +26.3% | 0.02% | +46.7% |
| Q4 2018 | $3,312,000 | -74.9% | 22,887 | -64.6% | 0.02% | -68.8% |
| Q3 2018 | $13,206,000 | +88.7% | 64,700 | +36.8% | 0.05% | +65.5% |
| Q2 2018 | $6,997,000 | +161.4% | 47,289 | +166.7% | 0.03% | +141.7% |
| Q1 2018 | $2,677,000 | – | 17,732 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |